73 Results
Sort By:
Published on December 15, 2022
Jim Geraghty Jim Geraghty, a seasoned biotech executive and a veteran of the orphan drug movement since its inception, took some time to talk to Damian Doherty about his new book, Inside the Orphan Drug Revolution. Jim gives an historical perspective of the leading protagonists who…
Published on October 14, 2022
The COVID-19 pandemic has turned RNA into a household word, but what new innovations and changes will we see in the RNA therapeutics space going forward and how many will actually reach the clinic? The last couple of years proved a turning point for biotech companies such as BioNTech and…
Published on July 12, 2022
Epic Bio, which aims to develop “ultracompact” therapies to modulate gene expression in vivo, today announced its launch and $55 million Series A financing. The biotech was founded by Stanley Qi, Ph.D., a co-inventor on the CRISPR patent held by the University of California. Epic will “revolutionize genetic medicine with…
Published on June 15, 2022
This year marks the 10-year anniversary of when CRISPR-Cas9 gene editing was first revealed to the world. Much has happened since then, including wide rollout in many sectors, development of CRISPR-based therapeutics and the discovery that the technology can also be used to develop highly accurate and affordable diagnostics. The…
Published on June 15, 2022
Deepak Asudani Deepak Asudani and his two children Ananya and Aarnav have published the first of a series of educational books on DNA and genetics aimed at schoolchildren who are curious to learn about what makes them unique whilst highlighting the similarities we share. Damian Doherty…
Published on May 17, 2022
A cytomegalovirus (CMV) vector-based gene therapy delivered monthly, by inhalation or intraperitoneally, reversed aging-associated decline in a mouse model. Exogenous telomerase reverse transcriptase or follistatin genes were each safely and effectively delivered. The treatment significantly improved biomarkers associated with healthy aging, and mice’s lifespans were increased up to 41% without…
Published on May 4, 2022
An insect odorant receptor will be added to Cardea Bio’s Biosignal Processing Unit (BPU) to detect infectious diseases like SARS-CoV-2 in the air in a collaboration with the Bill and Melinda Gates Foundation. The San Diego health tech company was founded in 2013 and has specialized in making and refining…
Published on April 8, 2022
Polygenic risk scores (PRS)—which quantify inherited risk by integrating multiple sites of DNA variation—promise a more personalized approach to medicine. For many years, academic groups have been grappling with the mechanics of creating PRS, relying on large-scale GWAS analyses from large patient cohorts like the UK Biobank and others to…
Published on February 2, 2022
Looking for an alternative to the problematic adeno-associated virus (AAV) as a delivery vehicle for gene therapies, Sarepta Therapeutics has signed a $57 million deal with GenEdit, which has developed a polymer nanoparticle platform for tissue-selective delivery called NanoGalaxy. The companies will collaborate to use NanoGalaxy and Sarepta’s gene editing technology…
Published on December 1, 2021
It’s already more than a $160 billion market and is expected to grow to almost $550 billion over the next ten years. But while companies and investors have learned how to profit handsomely from them, rare diseases are still a healthcare desert to most people who suffer from them. Of…
Published on December 1, 2021
By Pat Furlong and Sheila Moeschen Consider this: At 90 years old, my mother still spoke about the Nun from her grammar school who tapped her on the shoulder and said, “You are nothing like your sisters and brothers.” The sentence formed a toxin, a slow drip into the bloodstream…
Published on December 1, 2021
Sponsored content brought to you by Debra Miller first noticed that something was wrong when her four-year-old son Hawken had trouble keeping up with the other kids while playing soccer. After two long years of hospital visits and inconclusive tests, they finally received a proper diagnosis of Duchenne muscular dystrophy,…
Published on October 14, 2021
Cell therapy biotech Immusoft will partner Takeda to develop new cell therapies to target rare inherited metabolic disorders with central nervous system (CNS) manifestations and complications in a deal that could be worth more than $900M if all targets are met. Immusoft was founded in 2009 and is headquartered in…
Published on August 27, 2021
Sponsored content brought to you by: Debra Miller first noticed that something was wrong when her four-year-old son Hawken had trouble keeping up with the other kids while playing soccer. After two long years of hospital visits and inconclusive tests, they finally received a proper diagnosis of Duchenne muscular dystrophy,…
Published on August 25, 2021
There is a still a lot of ground to make up in encouraging young girls and women to follow their hearts into STEM careers where women continue to be underrepresented in industry positions. But that doesn’t mean women aren’t making their presence felt in jobs that can greatly influence the…